Healthcare Stocks Cardiol Therapeutics Announces Year-End 2023 Update on Operations Completed patient enrollment in the Phase II MAvERIC-Pilot study evaluating CardiolRx™ in… Ryan AllwayApril 2, 2024
Feature Healthcare Stocks Top News The Impact of Positive Phase 2 Trial Results on a Smaller Company A few weeks back, we covered the effect an Orphan Drug Designation… Robin LeffertsMarch 12, 2024
Feature Healthcare Stocks Top News The Impact of Orphan Drug Development on a Smaller Company Orphan drugs treat conditions with less than 200,000 patients annually in the… Robin LeffertsFebruary 6, 2024
Feature Healthcare Stocks Top News Distinguished Health Centers and Experts Lead Recurrent Pericarditis, Acute Myocarditis Clinical Trials Any clinical trial program relies heavily on its administrators, advisors, and designers.… Robin LeffertsJanuary 16, 2024
Healthcare Stocks Top News Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis Toronto, Ontario–(Newsfile Corp. – January 9, 2024) – Cardiol Therapeutics Inc. (NASDAQ: CRDL)… Ryan AllwayJanuary 9, 2024
